High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy

BACKGROUND: The high prevalence of type 2 diabetes mellitus (DM) among patients with colorectal cancer (CRC) is becoming a serious public health concern worldwide. FOLFOX4 chemotherapy is one of the most widely used adjuvant therapies in patients with stage III colon cancer after surgical resection....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Med Oncol
Main Authors: Yang, I-Ping, Miao, Zhi-Feng, Huang, Ching-Wen, Tsai, Hsiang-Lin, Yeh, Yung-Sung, Su, Wei-Chih, Chang, Tsung-Kun, Chang, Se-fen, Wang, Jaw-Yuan
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6704420/
https://ncbi.nlm.nih.gov/pubmed/31467597
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919866964
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados